Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Hagens Berman Sobol Shapiro LLPBeta Bionics (BBNX) Faces Securities Class Action Amid iLet FDA Compliance -- HBSSBeta Bionics, Inc. (NASDAQ: BBNX) faces a securities class action, which seeks to represent investors who purchased or otherwise acquired shares of the company's common stock between July 30, 2025 and February 24, 2026.The lawsuit follows a series of surprise revelations about the FDA's concerns over company's automated insulin delivery system ("iLet"), each of which sent the price of Beta Bionics shares sharply lower. National...
- Kaplan Fox & Kilsheimer LLPKaplan Fox Encourages Hims & Hers Health, Inc. (HIMS) Investors to Contact the Firm Before the Deadline on November 2, 2026 for a Leadership RoleKaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between August 4, 2025 and July 29, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in Hims & Hers and have suffered losses, you may CLICK HERE to contact us. You may...
- Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business UpdateCellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that it will host a conference call and webcast on Monday, September 14, 2026 to provide a business update.
- Strata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360ATLANTA, September 11, 2026--Strata Mental Health Solutions, the expert-led training and implementation partner preparing clinical networks to deliver psychedelic treatments, today announced it has been awarded one of the five U.S. HCP training grants awarded by Compass Pathways (Nasdaq: CMPS) to develop U.S. health care provider training programs for COMP360, Compass’ investigational psilocybin treatment, if approved.
- Hagens Berman Sobol Shapiro LLPHims & Hers Health (HIMS) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before November 2, 2026 Lead Plaintiff DeadlineHims & Hers Health, Inc. (NYSE: HIMS) and certain company executives now face a securities class action lawsuit stemming from the FTC's sweeping federal complaint against the company in which the Commission accuses Hims of serious business misconduct.Hagens Berman, which is actively investigating the alleged claims, encourages HIMS investors who suffered substantial losses to submit your losses now. Class Period: Aug. 4, 2025 -...
- "We're exhausted, but the residents are counting on us." - CUPE 4599 to hold information picket ahead of contract negotiations at Kensington Medical Center in TorontoToronto, September 11, 2026--The workers of CUPE 4599 provide quality care for the residents of Kensington Health Long-Term Care and Hospice in Toronto’s Kensington Market. The work is physically and psychologically demanding, but the workers show up every day to provide care for some of the most vulnerable members of the community because, they care. High workload, coupled with high stress and low pay has caused turnover at the home to skyrocket.
- Hagens Berman Sobol Shapiro LLPINVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. (REGN) Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action Lawsuit Before September 14, 2026 DeadlineHagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma.The news that the trial failed drove the price of Regeneron shares sharply lower and, along with the severe market reaction ($11 billion market cap wipeout),...
- Menlo Business BrokerageMenlo Business Brokerage Expands Team with Strategic HireTEMPE, Ariz., September 11, 2026--Menlo Business Brokerage today announced that Emily Stubbs has joined the firm as a business advisor. She will represent ABA practices, professional services firms, medical practices, and other businesses looking to sell, bringing a strategic and legally informed perspective to each transaction.
- WallachBeth Capital LLCWallachBeth Capital Announces Tenon Medical Warrant Inducement for Gross Proceeds of Approximately $2,872,338WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care...
- FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.Pharming today announced that the U.S. FDA has approved its sNDA for Joenja® as first treatment for children with APDS
- AdaptHealth Corp.AdaptHealth To Participate in Upcoming Investor ConferencesPLYMOUTH MEETING, Pa., September 11, 2026--AdaptHealth Corp. (NASDAQ: AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today announced today that they will participate in the following upcoming investor conferences:
- MEDIPAL HOLDINGS CORPORATIONMEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Dose First Patient in Global Phase I/II Trial of JR-446 for Mucopolysaccharidosis Type IIIBTOKYO & HYOGO, Japan, September 11, 2026--JCR and MEDIPAL announced that the first participant has been dosed in the global Phase I/II trial of JR-446 for mucopolysaccharidosis type IIIB.